title: Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets.
abstract: The efficacy of oral tigecycline treatment (2 mg/kg of body weight for 7 days) of Clostridium difficile infection (CDI) was evaluated in the gnotobiotic pig model, and its effect on human gut microflora transplanted into the gnotobiotic pig was determined. Tigecycline oral treatment improved survival, clinical signs, and lesion severity and markedly decreased concentrations of Firmicutes but did not promote CDI. Our data showed that oral tigecycline treatment has a potential beneficial effect on the treatment of CDI.
authors.affiliation: Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts, USA Department of Animal Resource and Science, Dankook University, Cheonan, Choongnam, South Korea.
authors.forename: Hyeun Bum
authors.initials: HB
authors.lastname: Kim
authors.affiliation: Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts, USA.
authors.forename: Quanshun
authors.initials: Q
authors.lastname: Zhang
authors.affiliation: Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts, USA.
authors.forename: Xingmin
authors.initials: X
authors.lastname: Sun
authors.affiliation: Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts, USA.
authors.forename: Gillian
authors.initials: G
authors.lastname: Beamer
authors.affiliation: Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts, USA.
authors.forename: Yuankai
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Infectious Disease and Global Health, Tufts University, North Grafton, Massachusetts, USA Saul.Tzipori@tufts.edu.
authors.forename: Saul
authors.initials: S
authors.lastname: Tzipori
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016360:Clostridioides difficile / Q000187:drug effects* / Q000254:growth & development; D004334:Drug Administration Schedule; D004761:Enterocolitis, Pseudomembranous / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D024841:Fluoroquinolones / Q000494:pharmacology; D005856:Germ-Free Life; D006801:Humans; D016209:Interleukin-8 / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000378:metabolism; D064307:Microbiota / Q000187:drug effects*; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D011744:Pyrimidinones / Q000494:pharmacology; D013552:Swine; D000078304:Tigecycline; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D016209:Interleukin-8; C585474:MBX-500; D011744:Pyrimidinones; D014640:Vancomycin; D000078304:Tigecycline; D008911:Minocycline